Jensa Morris: Why Low Molecular Weight Heparins Should Be the First Choice for VTE
Jensa Morris, Director of Smilow Hospitalist Service at Yale New Haven Hospital, shared a post on LinkedIn about a recent article by Youssef Saklawi et al, published in Journal of Hospital Medicine, adding:
“There are so many clinical interventions that we do reflexively despite a mountain of clinical evidence to the contrary.
Thank you Journal of Hospital Medicine and TWDFNR for reminding us that LMWH and not UFH should be first choice for patients requiring non-oral treatment for VTE, even for those who may later require thrombolysis or thrombectomy.”
Title: Things we do for no reason™: Routine use of unfractionated heparin for initial anticoagulation in venous thromboembolism
Authors: Youssef Saklawi, Mohamad Ali Tfaily, Bhargav Marthambadi, Adrian Umpierrez
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 28, 2026, 03:59Rahul Saha: JAMA The 49th Human Blood Group System
-
Sep 28, 2026, 01:51Ann Mullally: Expect to See Lots More Gene Therapy in Medicine in the Years Ahead
-
Sep 27, 2026, 15:49Rana Al-Hrout: Iron Deficency – Is Ferritin 15ng/mL or Less Still the Cutoff?
-
Sep 27, 2026, 15:49Ayushi Sharma: What I Thought Transfusion Medicine Would Be vs What It Actually Is
-
Sep 27, 2026, 15:48William Wallace: How Much Human Research Is Behind the Supplements We Take?
-
Sep 27, 2026, 15:46Franck Perraudin: Lp(a) Lowering Alone May Not Be Enough
-
Sep 27, 2026, 15:41Ahmed Hamandi: Sharing Real-World HSCT Experience at the Iraqi Society of Haematology Conference
-
Sep 27, 2026, 15:39Co-creating Digital Support With Young Stroke Survivors – European Stroke Organisation
-
Sep 27, 2026, 15:39Eleri Schiavone: Celebrating 80 Years of the Welsh Blood Service